PMC:7361216 / 2277-2716 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T25","span":{"begin":108,"end":111},"obj":"Body_part"},{"id":"T26","span":{"begin":136,"end":142},"obj":"Body_part"},{"id":"T27","span":{"begin":371,"end":383},"obj":"Body_part"},{"id":"T28","span":{"begin":401,"end":414},"obj":"Body_part"},{"id":"T29","span":{"begin":430,"end":438},"obj":"Body_part"}],"attributes":[{"id":"A25","pred":"fma_id","subj":"T25","obj":"http://purl.org/sig/ont/fma/fma62873"},{"id":"A26","pred":"fma_id","subj":"T26","obj":"http://purl.org/sig/ont/fma/fma62977"},{"id":"A27","pred":"fma_id","subj":"T27","obj":"http://purl.org/sig/ont/fma/fma82737"},{"id":"A28","pred":"fma_id","subj":"T28","obj":"http://purl.org/sig/ont/fma/fma62983"},{"id":"A29","pred":"fma_id","subj":"T29","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"The present Editorial highlights a study by Aliu and colleagues, entitled “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer” published in the current issue of the Journal of Neurochemistry, in which the authors have developed a therapy directed to a highly specific target to treat a rare neurologic disease where a carbohydrate component of the myelin sheath is attacked by antibody."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T10","span":{"begin":136,"end":142},"obj":"Body_part"},{"id":"T11","span":{"begin":401,"end":414},"obj":"Body_part"},{"id":"T12","span":{"begin":401,"end":407},"obj":"Body_part"}],"attributes":[{"id":"A10","pred":"uberon_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/UBERON_0000345"},{"id":"A11","pred":"uberon_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/UBERON_0000347"},{"id":"A12","pred":"uberon_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/UBERON_0000345"}],"text":"The present Editorial highlights a study by Aliu and colleagues, entitled “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer” published in the current issue of the Journal of Neurochemistry, in which the authors have developed a therapy directed to a highly specific target to treat a rare neurologic disease where a carbohydrate component of the myelin sheath is attacked by antibody."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T8","span":{"begin":344,"end":362},"obj":"Disease"}],"attributes":[{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0005071"}],"text":"The present Editorial highlights a study by Aliu and colleagues, entitled “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer” published in the current issue of the Journal of Neurochemistry, in which the authors have developed a therapy directed to a highly specific target to treat a rare neurologic disease where a carbohydrate component of the myelin sheath is attacked by antibody."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T31","span":{"begin":33,"end":34},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T32","span":{"begin":281,"end":282},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T33","span":{"begin":303,"end":304},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T34","span":{"begin":337,"end":338},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T35","span":{"begin":369,"end":370},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"The present Editorial highlights a study by Aliu and colleagues, entitled “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer” published in the current issue of the Journal of Neurochemistry, in which the authors have developed a therapy directed to a highly specific target to treat a rare neurologic disease where a carbohydrate component of the myelin sheath is attacked by antibody."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T22","span":{"begin":149,"end":156},"obj":"Chemical"},{"id":"T23","span":{"begin":166,"end":178},"obj":"Chemical"},{"id":"T25","span":{"begin":371,"end":383},"obj":"Chemical"}],"attributes":[{"id":"A22","pred":"chebi_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"},{"id":"A23","pred":"chebi_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/CHEBI_53590"},{"id":"A24","pred":"chebi_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/CHEBI_61420"},{"id":"A25","pred":"chebi_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/CHEBI_16646"}],"text":"The present Editorial highlights a study by Aliu and colleagues, entitled “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer” published in the current issue of the Journal of Neurochemistry, in which the authors have developed a therapy directed to a highly specific target to treat a rare neurologic disease where a carbohydrate component of the myelin sheath is attacked by antibody."}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T11","span":{"begin":355,"end":362},"obj":"http://purl.obolibrary.org/obo/OGMS_0000031"}],"text":"The present Editorial highlights a study by Aliu and colleagues, entitled “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer” published in the current issue of the Journal of Neurochemistry, in which the authors have developed a therapy directed to a highly specific target to treat a rare neurologic disease where a carbohydrate component of the myelin sheath is attacked by antibody."}

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T20","span":{"begin":166,"end":178},"obj":"Chemical"},{"id":"T22","span":{"begin":371,"end":383},"obj":"Chemical"}],"attributes":[{"id":"A20","pred":"chebi_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/CHEBI_53590"},{"id":"A21","pred":"chebi_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/CHEBI_61420"},{"id":"A22","pred":"chebi_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/CHEBI_16646"}],"text":"The present Editorial highlights a study by Aliu and colleagues, entitled “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer” published in the current issue of the Journal of Neurochemistry, in which the authors have developed a therapy directed to a highly specific target to treat a rare neurologic disease where a carbohydrate component of the myelin sheath is attacked by antibody."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T15","span":{"begin":0,"end":439},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The present Editorial highlights a study by Aliu and colleagues, entitled “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer” published in the current issue of the Journal of Neurochemistry, in which the authors have developed a therapy directed to a highly specific target to treat a rare neurologic disease where a carbohydrate component of the myelin sheath is attacked by antibody."}

{"project":"LitCovid-sample-PD-UBERON","denotations":[{"id":"T8","span":{"begin":136,"end":142},"obj":"Body_part"},{"id":"T9","span":{"begin":401,"end":414},"obj":"Body_part"}],"attributes":[{"id":"A8","pred":"uberon_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/UBERON_0000345"},{"id":"A9","pred":"uberon_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/UBERON_0000347"}],"text":"The present Editorial highlights a study by Aliu and colleagues, entitled “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer” published in the current issue of the Journal of Neurochemistry, in which the authors have developed a therapy directed to a highly specific target to treat a rare neurologic disease where a carbohydrate component of the myelin sheath is attacked by antibody."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"66","span":{"begin":104,"end":107},"obj":"Gene"},{"id":"70","span":{"begin":344,"end":362},"obj":"Disease"},{"id":"67","span":{"begin":371,"end":383},"obj":"Chemical"}],"attributes":[{"id":"A66","pred":"pubann:denotes","subj":"66","obj":"Gene:4099"},{"id":"A70","pred":"pubann:denotes","subj":"70","obj":"MESH:D020271"},{"id":"A67","pred":"pubann:denotes","subj":"67","obj":"MESH:D002241"}],"text":"The present Editorial highlights a study by Aliu and colleagues, entitled “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer” published in the current issue of the Journal of Neurochemistry, in which the authors have developed a therapy directed to a highly specific target to treat a rare neurologic disease where a carbohydrate component of the myelin sheath is attacked by antibody."}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T33","span":{"begin":104,"end":107},"obj":"Protein"}],"attributes":[{"id":"A33","pred":"uniprot_id","subj":"T33","obj":"https://www.uniprot.org/uniprot/Q567S4"}],"text":"The present Editorial highlights a study by Aliu and colleagues, entitled “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer” published in the current issue of the Journal of Neurochemistry, in which the authors have developed a therapy directed to a highly specific target to treat a rare neurologic disease where a carbohydrate component of the myelin sheath is attacked by antibody."}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T25","span":{"begin":108,"end":111},"obj":"Body_part"},{"id":"T26","span":{"begin":136,"end":142},"obj":"Body_part"},{"id":"T27","span":{"begin":371,"end":383},"obj":"Body_part"},{"id":"T28","span":{"begin":401,"end":414},"obj":"Body_part"},{"id":"T29","span":{"begin":430,"end":438},"obj":"Body_part"}],"attributes":[{"id":"A25","pred":"fma_id","subj":"T25","obj":"http://purl.org/sig/ont/fma/fma62873"},{"id":"A26","pred":"fma_id","subj":"T26","obj":"http://purl.org/sig/ont/fma/fma62977"},{"id":"A27","pred":"fma_id","subj":"T27","obj":"http://purl.org/sig/ont/fma/fma82737"},{"id":"A28","pred":"fma_id","subj":"T28","obj":"http://purl.org/sig/ont/fma/fma62983"},{"id":"A29","pred":"fma_id","subj":"T29","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"The present Editorial highlights a study by Aliu and colleagues, entitled “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer” published in the current issue of the Journal of Neurochemistry, in which the authors have developed a therapy directed to a highly specific target to treat a rare neurologic disease where a carbohydrate component of the myelin sheath is attacked by antibody."}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T10","span":{"begin":344,"end":362},"obj":"Disease"}],"attributes":[{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0005071"}],"text":"The present Editorial highlights a study by Aliu and colleagues, entitled “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer” published in the current issue of the Journal of Neurochemistry, in which the authors have developed a therapy directed to a highly specific target to treat a rare neurologic disease where a carbohydrate component of the myelin sheath is attacked by antibody."}

{"project":"LitCovid-sentences","denotations":[{"id":"T15","span":{"begin":0,"end":439},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The present Editorial highlights a study by Aliu and colleagues, entitled “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer” published in the current issue of the Journal of Neurochemistry, in which the authors have developed a therapy directed to a highly specific target to treat a rare neurologic disease where a carbohydrate component of the myelin sheath is attacked by antibody."}

{"project":"LitCovid-PubTator","denotations":[{"id":"66","span":{"begin":104,"end":107},"obj":"Gene"},{"id":"67","span":{"begin":371,"end":383},"obj":"Chemical"},{"id":"70","span":{"begin":344,"end":362},"obj":"Disease"}],"attributes":[{"id":"A66","pred":"tao:has_database_id","subj":"66","obj":"Gene:4099"},{"id":"A67","pred":"tao:has_database_id","subj":"67","obj":"MESH:D002241"},{"id":"A70","pred":"tao:has_database_id","subj":"70","obj":"MESH:D020271"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The present Editorial highlights a study by Aliu and colleagues, entitled “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer” published in the current issue of the Journal of Neurochemistry, in which the authors have developed a therapy directed to a highly specific target to treat a rare neurologic disease where a carbohydrate component of the myelin sheath is attacked by antibody."}